Floatz logo

Nicardipine

Malignant Hypertension

Haseki Training and Research HospitalSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Malignant Hypertension cohort.

Asset / SponsorPhaseRating
Labetalol
Haseki Training and Research Hospital
Phase 4BB

Same molecule, other indications

Nicardipine is also rated in:

hypertensive disorderActive
BB
Indicative · Phase 4
67 / 100
View asset →
ischemic strokeActive
BB
Indicative · Phase 4
66 / 100
View asset →
stroke disorderDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →